Réactifs et instruments pour l'immunologie, la biologie cellulaire et la biologie moléculaire.
 
> BV6 [1001600-56-1]

BV6 [1001600-56-1]

Imprimer Imprimer
Identifiez-vous

Référence HY-16701-5mg

Conditionnement : 5mg

Marque : MedChemExpress

Contactez votre distributeur local :


Téléphone : +1 850 650 7790

Description

BV6 is an antagonist of cIAP1 and XIAP, members of the inhibitors of apoptosis (IAP) family. BV6 shows an IC50 of 7.2 μM in MTS assays in HCC193 cells. BV6 can be used in the research of endometrial cancer and endometriosis[1][2].

IC50 & Target

IAP[1]
In Vitro

BV6 (250 nM-30 μM, 24 h) induces apoptosis in HCC193 and H460 lung cancer cell lines in a concentration- and time-dependent manner. BV6 can also enhance the sensitivity of HCC193 and H460 cell lines to radiation[1].
BV6 (1μM 24 h; 5 μM, 48 h) significantly sensitizes the cell to radiation (HCC193-DER=1.38, at 1 μM BV6; H460-DER=1.42, at 5 μM BV6)[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

BV6 Related Antibodies

Cell Viability Assay[1]

Cell Line: HCC193 cells, H460 cells
Concentration: 250 nM, 500 nM, 1 μM, 3 μM, 5 μM, 10 μM, 20 μM, 30 μM
Incubation Time: 24 hours
Result: Decreased cell survival percentage for HCC193 with an IC50 of 7.2μM.
Decreased the cell viability of H460 cells by about 60% at 30 μM.

Western Blot Analysis[1]

Cell Line: HCC193 cells, H460 cells
Concentration: 0.25 μM, 0.5 μM, 1 μM, 5 μM
Incubation Time: 1, 14, 24 hours
Result: Reduced the expression of cIAP1 within one hour and gradually decreased XIAP with increased incubation time for both cell lines.
Reduced the expression of cIAP1 with 0.25μM and gradually decreased XIAP with increasing concentration for both cell lines.

ELISA Assay[1]

Cell Line: HCC193 cells, H460 cells
Concentration: 1 μM, 5 μM
Incubation Time: 12 hours
Result: Induced enhancement of the secretion of TNFα in HCC193 cells.
Did not enhance the secretion of TNFα in H460 cells.
In Vivo

BV6 (10 mg/kg, twice weekly for 4 weeks, i.p.) attenuated the intensity of IAPs expression[2].
BV6 (10 mg/kg, twice weekly for 4 weeks, i.p.) reduces the total number of lesions and the percentage of Ki67-positive cells compared to the control[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female endometriosis mice modeling by estradiol valerate (HY-B0672) at the dosage 0.5 µg/mouse/week s.c injected (6 weeks of age, BALB/c)[2].
Dosage: 10 mg/kg
Administration: a single i.p. injection,twice weekly for 4 weeks
Result: Attenuated the intensity of IAPs expression.
Masse moléculaire

1205.57

Formule

C70H96N10O8
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

O=C(NCCCCCCNC([C@@H](NC([C@H](CCC1)N1C([C@H](C2CCCCC2)NC([C@H](C)NC)=O)=O)=O)C(C3=CC=CC=C3)C4=CC=CC=C4)=O)[C@@H](NC([C@H](CCC5)N5C([C@H](C6CCCCC6)NC([C@H](C)NC)=O)=O)=O)C(C7=CC=CC=C7)C8=CC=CC=C8
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
Solvant et solubilité
In Vitro: 

DMSO : ≥ 100 mg/mL (82.95 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 0.8295 mL 4.1474 mL 8.2948 mL
5 mM 0.1659 mL 0.8295 mL 1.6590 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (2.07 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (2.07 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Pureté et documentation
Références

Vous serez peut-être également intéressé par les produits suivants :



Référence
Description
Cond.
Prix HT